8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

Form 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): July 24, 2018  

PSYCHEMEDICS CORPORATION
(Exact Name of Registrant as Specified in Charter)

Deleware	1-13738	58-1701987
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

289 Great Road, Acton, Massachusetts 01720

(Address of Principal Executive Offices) (Zip Code)

(978) 206-8220
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
	[   ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[   ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	[   ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [   ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

Item 2.02. Results of Operations and Financial Condition.

On July 24, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Limitation on Incorporation by Reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1. Press release dated July 24, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PSYCHEMEDICS CORPORATION
Date: July 24, 2018	By:	/s/ Neil Lerner
		Neil Lerner
		Vice President, Finance

EX-99.1 2 exh_991.htm PRESS RELEASE

EXHIBIT 99.1

Psychemedics Announces 2Q Record Revenues

Declares 88th Consecutive Quarterly Dividend

ACTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2018.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 7, 2018, to be paid on August 17, 2018.  This will be the Company’s 88^th consecutive quarterly dividend.

The Company’s revenue for the quarter ended June 30, 2018 was $10.8 million versus $9.7 million for the comparable period in 2017, an increase of 11%.  Net income for the quarter ended June 30, 2018 was $1.2 million or $0.21 per diluted share, versus $0.9 million or $0.16 per diluted share, for the comparable period last year, an increase of 30%.  Revenue for the six months ended June 30, 2018 was $21.7 million versus $19.9 million for the comparable period in 2017, an increase of 9%.  Net income for the six months ended June 30, 2018 and 2017 was $2.4 million or $0.44 per diluted share.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"Second quarter revenues were a record for any second quarter in the Company's history. Our domestic revenues continued to show strong growth, increasing 15%, which, as in the first quarter, was largely attributable to our Transportation and Oil and Gas market segments. Our international business (primarily Brazil) was up 4%. This was significantly impacted by a change in the Brazil exchange rate. International revenue would have been up 16% for the quarter compared to the same period in 2017 and total revenue would have increased 15%, if the exchange rate had remained the same.

"Earnings growth for the quarter of 30% was primarily driven by increased revenue.  In addition, the Company’s effective tax rate decreased from 47% in the second quarter of 2017 to 43% in the current quarter. This reflects the reduction in the U.S. federal income tax rate which is partially offset by Brazilian income taxes.  While we were encouraged with the strong increase in earnings, they would have been even better without the negative impact of $0.04 per diluted share from the change in the Brazil exchange rate.

"We are encouraged by the continuing strength and momentum in our domestic business and also look forward to the expansion of the Brazil market later this year when professional drivers are required to renew their licenses every 2 1/2 years instead of the current 5 years. This expansion is by law and would virtually double the market size as it unfolds.

“The Company’s balance sheet remains strong with $7.7 million in cash and $9.3 million of working capital.  The total equipment financing obligation outstanding was $2.9 million as of June 30, 2018.  Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow.  Therefore, we are pleased to declare our quarterly dividend $0.18 per share. This dividend represents our 88th consecutive quarterly dividend.”

Contact:
Neil Lerner
Vice President of Finance
(978) 206-8220
Neill@psychemedics.com

Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is www.psychemedics.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, sales and marketing strategies, U.S. and foreign drug testing laws and regulations and the enforcement of such laws and regulations, required investments in plant, equipment and people and new test development) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, costs of capacity expansion, U.S. and foreign government regulation, including but not limited to FDA regulations, Brazilian laws and regulations, proposed laws and regulations, currency risks, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s  ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.  The forward-looking statements contained herein speak only of the Company's expecta­tions as of the date of this press release. The Company express­ly disclaims any obligation or undertaking to release publicly any updates or revi­sions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based.

Psychemedics Corporation
Consolidated Statements of Income
(in thousands, except per share amounts)
(UNAUDITED)
	Three Months Ended					Six Months Ended
	June 30,					June 30,
		2018		2017			2018		2017
Revenues	$	10,787	$	9,684		$	21,722	$	19,893
Cost of revenues		5,615		5,075			11,195		9,968
Gross profit		5,172		4,609			10,527		9,925
Operating Expenses:
General & administrative		1,457		1,334			3,308		2,809
Marketing & selling		1,301		1,244			2,540		2,487
Research & development		358		321			717		651
Total Operating Expenses		3,116		2,899			6,565		5,947
Operating income		2,056		1,710			3,962		3,978
Other income (expense)		24		(12	)		56		(34	)
Net income before provision for income taxes		2,080		1,698			4,018		3,944
Provision for income taxes		903		791			1,590		1,537
Net income	$	1,177	$	907		$	2,428	$	2,407
Diluted net income per share	$	0.21	$	0.16		$	0.44	$	0.44
Dividends declared per share	$	0.18	$	0.15		$	0.36	$	0.30

Psychemedics Corporation
Consolidated Balance Sheets
(in thousands, except par value)
(UNAUDITED)
	June 30,			December 31,
		2018			2017
ASSETS
Current Assets:
Cash and cash equivalents	$	7,721		$	8,165
Accounts receivable, net of allowance for doubtful accounts
of $77 in 2018 and $64 in 2017		5,195			4,488
Prepaid expenses and other current assets		1,465			1,212
Total Current Assets		14,381			13,865
Fixed Assets, net of accumulated amortization and depreciation
of $13,181 in 2018 and $11,670 in 2017		11,129			11,811
Other assets		915			832
Total Assets	$	26,425		$	26,508
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable	$	1,117		$	398
Accrued expenses		3,014			2,870
Current portion of long-term debt		957			957
Total Current Liabilities		5,088			4,225
Long-term debt		1,942			2,420
Deferred tax liabilities, long-term		1,138			1,243
Total Liabilities		8,168			7,888
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized,
no shares issued or outstanding		--			--
Common stock, $0.005 par value; 50,000 shares authorized
6,175 shares issued in 2018 and 6,160 shares issued in 2017		31			31
Accumulated other comprehensive loss		(1,403	)		(238	)
Additional paid-in capital		31,208			31,022
Accumulated deficit		(1,497	)		(2,113	)
Less - Treasury stock, at cost, 668 shares		(10,082	)		(10,082	)
Total Shareholders' Equity		18,257			18,620
Total Liabilities and Shareholders' Equity	$	26,425		$	26,508

EX-99.1

EdgarFiling